BDSX Logo

Biodesix, Inc. (BDSX) 

NASDAQ
Market Cap
$195.99M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
150 of 776
Rank in Industry
7 of 42

Largest Insider Buys in Sector

BDSX Stock Price History Chart

BDSX Stock Performance

About Biodesix, Inc.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer …

Insider Activity of Biodesix, Inc.

Over the last 12 months, insiders at Biodesix, Inc. have bought $424,144 and sold $219,504 worth of Biodesix, Inc. stock.

On average, over the past 5 years, insiders at Biodesix, Inc. have bought $28.57M and sold $195,519 worth of stock each year.

Highest buying activity among insiders over the last 12 months: SCHULER JACK W () — $682,923. PATIENCE JOHN (Chairman) — $311,130. Strobeck Matthew (director) — $167,748.

The last purchase of 20,000 shares for transaction amount of $27,180 was made by Kennedy Lawrence T. Jr () on 2024‑11‑06.

List of Insider Buy and Sell Transactions, Biodesix, Inc.

2024-11-06Purchase
20,000
0.0139%
$1.36$27,180-0.66%
2024-11-05Purchase
100,253
0.0679%
$1.36$136,585-0.91%
2024-11-05Purchase
51,200
0.0348%
$1.36$69,888-1.10%
2024-11-05Purchasedirector
40,000
0.0278%
$1.40$55,916-3.43%
2024-11-05PurchaseChairman
75,000
0.0516%
$1.38$103,710-2.37%
2024-11-05Purchasedirector
22,500
0.0154%
$1.37$30,866-1.59%
2024-08-12SalePresident & CEO
963
0.0007%
$1.57$1,514+9.01%
2024-08-12SaleCFO, Sec'y & Treasurer
251
0.0002%
$1.57$395+9.01%
2024-08-12SaleChief Development Officer
111
<0.0001%
$1.57$174+9.01%
2024-08-12SaleChief Commercial Officer
120
<0.0001%
$1.57$189+9.01%
2024-08-12SaleChief Accounting Officer
54
<0.0001%
$1.57$85+9.01%
2024-08-09SalePresident & CEO
2,781
0.0024%
$1.60$4,452+10.06%
2024-08-09SaleCFO, Sec'y & Treasurer
724
0.0006%
$1.60$1,159+10.06%
2024-08-09SaleChief Development Officer
320
0.0003%
$1.60$512+10.06%
2024-08-09SaleChief Commercial Officer
345
0.0003%
$1.60$552+10.06%
2024-08-09SaleChief Accounting Officer
155
0.0001%
$1.60$248+10.06%
2024-05-09SalePresident & CEO
3,764
0.0031%
$1.48$5,569+5.81%
2024-05-09SaleCFO, Sec'y & Treasurer
980
0.0008%
$1.48$1,450+5.81%
2024-05-09SaleChief Development Officer
434
0.0004%
$1.48$642+5.81%
2024-05-09SaleChief Commercial Officer
468
0.0004%
$1.48$692+5.81%

Insider Historical Profitability

<0.0001%
SCHULER JACK W
30894935
21.2809%
$1.35290<0.0001%
Kennedy Lawrence T. Jr
10376024
7.1472%
$1.3540+22.69%
Strobeck Matthewdirector
2606879
1.7957%
$1.3560+0.18%
PATIENCE JOHNChairman
2153298
1.4832%
$1.35100<0.0001%
Hutton ScottPresident & CEO
518368
0.3571%
$1.35218<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Birchview Capital Lp$7.42M4.535.19M0%+$00.41
Aigh Capital Management Llc$4.75M2.93.32M-28.72%-$1.91M2.72
Telemark Asset Management LLC$1.9M1.161.33M+1,644.74%+$1.79M0.21
ESSEX INVESTMENT MANAGEMENT CO LLC$1.32M0.81925,614+1.39%+$18,116.670.27
Wells Fargo$1.28M0.78893,203+1.08%+$13,656.51<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.